相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Mutant Gq/11 Promote Uveal Melanoma Tumorigenesis by Activating YAP
Fa-Xing Yu et al.
CANCER CELL (2014)
Hippo-Independent Activation of YAP by the GNAQ Uveal Melanoma Oncogene through a Trio-Regulated Rho GTPase Signaling Circuitry
Xiaodong Feng et al.
CANCER CELL (2014)
Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer
Avnish Kapoor et al.
CELL (2014)
KRAS and YAP1 Converge to Regulate EMT and Tumor Survival
Diane D. Shao et al.
CELL (2014)
Clinical Profiling of BCL-2 Family Members in the Setting of BRAF Inhibition Offers a Rationale for Targeting De Novo Resistance sing BH3 Mimetics
Dennie T. Frederick et al.
PLOS ONE (2014)
Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer
Luping Lin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Downstream of Mutant KRAS, the Transcription Regulator YAP Is Essential for Neoplastic Progression to Pancreatic Ductal Adenocarcinoma
Weiying Zhang et al.
SCIENCE SIGNALING (2014)
Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS Mutant Cancer Models
Ryan B. Corcoran et al.
CANCER CELL (2013)
Molecular Characterization of Acquired Resistance to the BRAF Inhibitor Dabrafenib in a Patient with BRAF-Mutant Non-Small-Cell Lung Cancer
Charles M. Rudin et al.
JOURNAL OF THORACIC ONCOLOGY (2013)
Bcl-2/Bcl-xL Inhibition Increases the Efficacy of MEK Inhibition Alone and in Combination with PI3 Kinase Inhibition in Lung and Pancreatic Tumor Models
Nguyen Tan et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study
Pasi A. Jaenne et al.
LANCET ONCOLOGY (2013)
Genetic diversity among pandemic 2009 influenza viruses isolated from a transmission chain
Sarah L. Fordyce et al.
VIROLOGY JOURNAL (2013)
Relief of Feedback Inhibition of HER3 Transcription by RAF and MEK Inhibitors Attenuates Their Antitumor Effects in BRAF-Mutant Thyroid Carcinomas
Cristina Montero-Conde et al.
CANCER DISCOVERY (2013)
β-Catenin-Driven Cancers Require a YAP1 Transcriptional Complex for Survival and Tumorigenesis
Joseph Rosenbluh et al.
CELL (2012)
Inhibition of MEK and PI3K/mTOR Suppresses Tumor Growth but Does Not Cause Tumor Regression in Patient-Derived Xenografts of RAS-Mutant Colorectal Carcinomas
Giorgia Migliardi et al.
CLINICAL CANCER RESEARCH (2012)
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Anirudh Prahallad et al.
NATURE (2012)
Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Survival in BRAF V600-Mutant Advanced Melanoma Treated with Vemurafenib
Jeffrey A. Sosman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The YAP and TAZ transcription co-activators: Key downstream effectors of the mammalian Hippo pathway
Wanjin Hong et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2012)
EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of BRAF-Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib
Ryan B. Corcoran et al.
CANCER DISCOVERY (2012)
RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome
Bo Li et al.
BMC BIOINFORMATICS (2011)
FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR
Trever G. Bivona et al.
NATURE (2011)
RAS oncogenes: weaving a tumorigenic web
Yuliya Pylayeva-Gupta et al.
NATURE REVIEWS CANCER (2011)
Hippo Pathway Effector Yap Is an Ovarian Cancer Oncogene
Chad A. Hall et al.
CANCER RESEARCH (2010)
The Hippo Signaling Pathway in Development and Cancer
Duojia Pan
DEVELOPMENTAL CELL (2010)
Cytoplasmic ASPP1 inhibits apoptosis through the control of YAP
Arnaud M. Vigneron et al.
GENES & DEVELOPMENT (2010)
Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial
Arnaud D. Roth et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Differential expression analysis for sequence count data
Simon Anders et al.
GENOME BIOLOGY (2010)
Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers
Alex A. Adjei et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control
Bin Zhao et al.
GENES & DEVELOPMENT (2007)
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
A Subramanian et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
The Hippo signaling pathway coordinately regulates cell proliferation and apoptosis by inactivating Yorkie, the Drosophila homolog of YAP
JB Huang et al.
CELL (2005)
Targeting ras signalling pathways in cancer therapy
J Downward
NATURE REVIEWS CANCER (2003)
分享论文
